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Abstract 1 
Background - Pre-eclampsia is a pregnancy-specific disorder resulting in hypertension and 2 
multi-organ dysfunction. There is growing evidence that these effects persist after pregnancy. 3 
We aimed to systematically evaluate and quantify the evidence on the relationship between 4 
pre-eclampsia and the future risk of cardiovascular diseases. 5 
Methods and Results - We studied the future risk of heart failure, coronary heart disease, 6 
composite cardiovascular disease, death due to coronary heart or cardiovascular disease, 7 
stroke and stroke death following pre-eclampsia. A systematic search of MEDLINE and 8 
EMBASE was performed to identify relevant studies. We used random effects meta-analysis 9 
to determine the risk. Twenty-two studies were identified with >6.4 million women including 10 
>258,000 women with pre-eclampsia. Meta-analysis of studies that adjusted for potential 11 
confounders demonstrated that pre-eclampsia was independently associated with an increased 12 
risk of future heart failure (RR 4.19, 95% CI 2.09, 8.38), coronary heart disease (RR 2.50, 13 
95% CI 1.43, 4.37), cardiovascular disease death (RR 2.21, 95% CI 1.83, 2.66) and stroke 14 
(RR 1.81, 95% CI 1.29, 2.55). Sensitivity analyses showed that pre-eclampsia continued to be 15 
associated with an increased risk of future coronary heart disease, heart failure and stroke 16 
after adjusting for age (RR 3.89, 95% CI 1.83, 8.26), body mass index (RR 3.16, 95% CI 17 
1.41, 7.07) and diabetes (4.19, 95% CI 2.09, 8.38). 18 
Conclusions - Pre-eclampsia is associated with a four-fold increase in future incident heart 19 
failure and a two-fold increased risk in coronary heart disease, stroke and death due to 20 
coronary heart or cardiovascular disease. Our study highlights the importance of lifelong 21 
monitoring of cardiovascular risk factors in women with a history of pre-eclampsia. 22 
 23 
Key words – preeclampsia/pregnancy, cardiovascular disease risk factors, pregnancy and 24 
postpartum 25 26 
4  
Introduction 1 
Pre-eclampsia is a major cause of maternal mortality worldwide 1 and affects 2-8% of 2 
all pregnancies.2, 3 It is confined to pregnancy and defined as onset of hypertension after 20 3 
weeks of gestation with either proteinuria, organ dysfunction or uteroplacental dysfunction.4 4 
The pathogenesis of pre-eclampsia remains poorly understood and is thought to be due to the 5 
failure of spiral artery remodelling in the placenta causing placental hypo-perfusion and 6 
hypoxia. The resultant oxidative stress triggers an excessive systemic inflammatory response, 7 
which causes endothelial dysfunction and vasoconstriction leading to systemic hypertension 8 
and end organ hypo-perfusion.2, 5 There is growing evidence that these effects on end organs 9 
persist after pregnancy. 10 
Cardiovascular disease is a leading cause of mortality globally and also of maternal 11 
death in the UK and US.6, 7 Several studies have examined the relationship between pre-12 
eclampsia and future incident cardiovascular disease, though the literature has been 13 
inconsistent. Some studies reporting significantly higher risks of composite cardiovascular 14 
events or heart failure,8, 9 while others have not demonstrated such relationships.10, 11  15 
It is unclear whether pre-eclampsia is an independent risk factor for future 16 
cardiovascular disease or an early marker of women with high-risk profiles for future 17 
cardiovascular disease. Factors that predispose women to pre-eclampsia are also found in the 18 
risk profile for cardiovascular diseases. These include obesity,12 metabolic abnormalities, 19 
dyslipdaemia, insulin resistance,13 heightened inflammatory responses, hypercoagulable 20 
states and endothelial dysfunction.14 Alternatively, the body may not fully recover from the 21 
damage to the vascular, endothelial and metabolic systems associated with pre-eclampsia and 22 
may manifest in later life with future cardiovascular events.2 Lipid deposition in the spiral 23 
artery walls is more commonly seen in pre-eclamptic than healthy pregnancies, which mimic 24 
the early stages of atherosclerosis.15  25 
5  
Although the national guidance in the US 16, 17 and the UK 18 recommend that, 1 
following a diagnosis of pre-eclampsia, women should be counselled and followed-up for 2 
cardiovascular risk modification, no conclusive evidence exists for an effective risk reduction 3 
strategy  and such follow-up is probably not done in practice. In addition, more recent studies 4 
have shown non-significant and conflicting data for the level of cardiovascular risk following 5 
pre-eclampsia.19, 20 There is a need to re-evaluate and quantify the risk of cardiovascular 6 
events following pre-eclampsia to guide future management and risk modification, in order to 7 
contribute to guidelines for clinicians. To this end, we conducted a systematic review and 8 
meta-analysis of contemporary studies (published 2005-2015) to quantify the future risk of 9 
cardiovascular events in women following pre-eclampsia. 10 
 11 
Methods 12 
Eligibility criteria  13 
We selected studies investigating the long-term cardiovascular outcomes of women 14 
with and without pre-eclampsia published in the English language between 2005 and August 15 
2015. There was no restriction on the definition of pre-eclampsia. Primary cardiovascular 16 
outcomes were heart failure, coronary heart disease, death due to coronary heart disease, 17 
composite cardiovascular disease defined as a combination of cardiac, cerebrovascular and 18 
peripheral vascular disease, death due to composite cardiovascular disease, stroke and stroke 19 
death. The included studies had at least two groups (one with pre-eclampsia and one without 20 
pre-eclampsia) and reported sufficient data to allow for accurate risk estimates to be 21 
calculated. Studies assessing outcomes during antepartum or before 6 weeks’ post-partum 22 
were excluded. There was no restriction based on cohort type, study design or duration of 23 
follow-up. 24 
 25 
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Data sources and searches 1 
MEDLINE and EMBASE were searched using OVID SP for studies from January 2 
2005 to August 2015. The detailed search strategy and search terms are outlined in Appendix 3 
1. The relevant primary studies for inclusion on this study were extracted from a 4 
comprehensive programme of evidence synthesis which explored the association between 5 
pre-eclampsia and adverse cardiovascular or metabolic outcomes. A search for additional 6 
articles was also conducted through manual searching of the bibliography of relevant review 7 
articles and meta-analyses. 8 
 9 
Study selection and data extraction 10 
Four reviewers (PW, RH, RAK and AB) screened all titles that met the inclusion 11 
criteria. This was followed by a screen of the remaining abstracts. The full articles were 12 
screened by the same four reviewers and the final decision to include studies was made by 13 
PW, RH and CSK. Independent double data extraction was done by four reviewers (PW, RH, 14 
RAK and AB). Data was collected on study design, year, country, number of participants, 15 
mean age, parity, cohort characteristics, definition and ascertainment of pre-eclampsia, 16 
ascertainment of outcomes, timing of assessment, adequacy of follow-up and results. The 17 
information was obtained from published data. 18 
 19 
Study quality assessment 20 
Study quality was assessed against the Newcastle-Ottawa Quality Assessment Scale 21 
(PQAS) for cohort studies.21 Our gold standard for each of the criteria were: selection of 22 
exposed cohort from the general population of pregnant women; selection of non-exposed 23 
cohort from the same population; reliable ascertainment of exposure such that the likelihood 24 
of controls being misclassified as having pre-eclampsia when they did not or cases being 25 
7  
wrongly classified as not having pre-eclampsia was minimized; exclusion of women who had 1 
cardiovascular outcome of interest prior to or during pregnancy; comparable cohort where 2 
confounders, in particular age, smoking and other cardiovascular risk factors, were accounted 3 
for; assessment of outcomes prospectively or through linkage of records and/or independent 4 
blind assessment; follow-up duration for at least 1 year post-partum; and less than 10% of the 5 
study participants in each cohort being lost to follow-up. 6 
 7 
Data synthesis and analysis 8 
We used RevMan Version 5.3.5 (Nordic Cochrane Centre) to conduct random effects 9 
meta-analysis using the inverse variance method for pooling log risk ratios (RRs). We used 10 
random effects because the studies were conducted in a wide range of settings in different 11 
populations, hence the need to take heterogeneity into account for the pooled effect estimate. 12 
Where possible, we chose to pool adjusted risk estimates from primary studies and when 13 
these data were not available, raw data were used to calculate unadjusted risk estimates. 14 
Analysis was performed considering adjusted and unadjusted group separately. Statistical 15 
heterogeneity was assessed using the I2 statistic where I2 values of 30-60% represented 16 
moderate level of heterogeneity.22 Where there was greater than a moderate degree of 17 
heterogeneity, we performed leave-one-out analysis to identify studies which contributed to 18 
high degree of heterogeneity. In the case for an analysis where there is more than 10 studies 19 
and little evidence of heterogeneity, we performed funnel plots to assess for publication bias. 20 
 21 
Results 22 
Description of studies included in analysis 23 
The initial MEDLINE and EMBASE search produced 9,964 titles and abstracts, 24 
following which 22 studies were included in the analysis (Figure 1). The studies examined 25 
8  
6,456,379 women in total (ranges from 137 to 2,066,230 women in each study). Studies 1 
recruiting patients from the same population were paired to avoid duplication of participant 2 
numbers.8, 23-25 3 
Details of study design and demographics are shown in Supplemental Table 1. From 4 
the 17 studies that reported the number of women in each group, there were 258,275 women 5 
with pre-eclampsia and 4,006,431 controls. 4 studies recruited primiparous women only,8, 19, 6 
24, 26 while 17 studies included women of any parity.9-11, 23, 25, 27-38 Studies reporting a mean or 7 
median age at enrolment ranged from 23.4 to 32.3 years while follow-up ranged from 6 8 
weeks’ post-partum to 39.4 years. 9 
 10 
Quality assessment of included studies 11 
The study quality was evaluated using the Newcastle-Ottawa Quality Assessment 12 
Scale (NOQAS) for cohort studies 21 as shown in Supplemental Tables 2 and 3. 19 studies 13 
had reliable methods of ascertaining pre-eclampsia from databases,8, 9, 19, 23-26, 30, 32, 35, 36 14 
medical records,10, 11, 20, 28, 34 prospective measurements,29, 33 or through completion of 15 
questionnaire with trained staff.30, 31 19 studies used reliable methods of obtaining 16 
cardiovascular outcomes either from databases,8-10, 19, 23-26, 28, 32, 34-36 medical records,11 17 
prospective measurements with echocardiography,33, 38 or through completion of 18 
questionnaire with trained staff.29-31 There was adequate follow-up (>90%) in 17 studies.8, 9, 11, 19 
23-28, 30-36, 38 18 studies used adjusted analyses.8, 9, 19, 20, 23-26, 28-33, 35-38 20 
 21 
Determining pre-eclampsia and results of studies 22 
Various methods were used to ascertain pre-eclampsia, with the most common being 23 
the International Society of the Studies of Hypertension in Pregnancy (ISSHP) (2014) 24 
definition.4 Supplemental Table 4 shows the results of the studies. 25 
9  
 1 
Pooled analysis of pre-eclampsia and cardiovascular outcomes 2 
The risk of heart failure with pre-eclampsia is shown in Figure 2. The pooled results 3 
of 7 studies 8, 10, 23, 31, 33, 35, 38 suggest a 3.6-fold increased risk of heart failure with pre-4 
eclampsia (risk ratio (RR) 3.62, 95% CI 2.25, 5.85, I2=83%, 2,764,824 participants). The risk 5 
increases to over four-fold for the adjusted studies 10, 23, 35, 38 (adjusted risk ratio (aRR) 4.19, 6 
95% CI 2.09, 8.38; I2=71%, 1,986,285 participants). The factors that have been adjusted for 7 
in the studies are shown in Supplemental Table 3. We performed leave out analyses to 8 
explore the sources of heterogeneity (Supplemental Table 6). The heterogeneity was mainly 9 
driven by the Mannisto 2013 study,10 if this study was excluded, heterogeneity was reduced 10 
to 46% in the adjusted analysis (aRR 5.57, 95% CI 3.14, 9.88). 11 
The relationship between pre-eclampsia and future risk of coronary heart disease and 12 
coronary heart disease death is shown in Figure 3 and 4. For coronary heart disease there was 13 
a two-fold increase risk of events with pre-eclampsia (RR 2.11, 95% CI 1.60, 2.77, I2=87%, 14 
3,239,797 participants). The risk was even greater in the adjusted studies 10, 19, 23, 25, 31, 35, 37 15 
(aRR 2.50, 95% CI 1.43, 4.37, I2=89%, 2,068,673 participants). The heterogeneity was 16 
mainly driven by the Lin 2011 study,23 if this study was excluded, heterogeneity was reduced 17 
to 66% in the adjusted analysis (aRR 1.67, 95% CI 1.19, 2.33. Supplemental Table 6). The 4 18 
adjusted studies 10, 19, 34, 36 reporting coronary heart disease death also show a two-fold 19 
increased risk with pre-eclampsia (aRR 2.10, 95% CI 1.25, 3.51, I2=64%, 677,378 20 
participants). The heterogeneity was mainly driven by the Bhattacharya 2012 study,19 if this 21 
study was excluded, heterogeneity was reduced to 2% in the adjusted analysis (aRR 2.63, 22 
95% CI 1.74, 3.98. Supplemental Table 6). 23 
The risk of composite cardiovascular disease and cardiovascular disease death with 24 
pre-eclampsia is shown in Supplemental Figure 1 and Figure 5. The pooled results from 6 25 
10  
studies 10, 11, 20, 23, 27, 32 with 1,398,119 participants suggest a significantly increased risk of 1 
cardiovascular disease (RR 1.65, 95% CI 1.36, 2.01, I2=42%). However, the results were not 2 
statistically significant for the 3 studies 10, 20, 23 that adjusted for baseline confounders prior to 3 
pregnancy (aRR 1.85, 95% CI 0.80, 4.29, I2=72%). For cardiovascular disease death, the 4 
pooled results of 4 studies 23-25, 28, 36 with 2,614,180 participants suggest a two-fold increase 5 
in cardiovascular disease death with pre-eclampsia (aRR 2.21, 95% CI 1.83, 2.66, I2=54%). 6 
All 4 studies adjusted for potential confounders. 7 
Figure 6 and Supplemental Figure 2 show the results for pooled analysis for studies 8 
on pre-eclampsia and stroke and stroke death. For stroke, there was a two-fold increased risk 9 
of events with pre-eclampsia (RR 1.71, 95% CI 1.38, 2.11, I2=69%, 4,906,182 participants). 10 
This increase in risk persisted in studies which adjusted for confounders (aRR 1.81, 95% CI 11 
1.29, 2.55, I2=74%, 4,131,344 participants).9, 10, 19, 25, 35, 37 The heterogeneity was mainly 12 
driven by the Bhattacharya 2012 study,19 if this study was excluded, heterogeneity was 13 
reduced to 24% in the adjusted analysis (aRR 2.04, 95% CI 1.60, 2.60. Supplemental Table 14 
6). 2 studies reported stroke death showed a two-fold increased risk with pre-eclampsia, 15 
however the result was not statistically significant (aRR 1.97, 95% CI 0.80, 4.88, I2=86%). 16 
 17 
Sensitivity analysis for follow-up time 18 
We conducted sensitivity analyses to consider the effect of follow-up time for 19 
cardiovascular outcomes that were significant in the adjusted studies (Table 1). The risk of 20 
heart failure was the highest 1-10 years (aRR 8.42, 95% CI 4.39, 16.17) after the pre-21 
eclamptic pregnancy compared with <1 year (aRR 4.10, 95% CI 2.90, 5.80) or >10 years 22 
(aRR 1.60, 95% CI 0.73, 3.50) post-partum. For coronary heart disease (aRR 3.10, 95% CI 23 
1.56, 6.16) and stroke (aRR 2.22, 95% CI 1.73, 2.85), the increase in risk was significant 24 
within the first year following delivery compared to other time points. In cardiovascular 25 
11  
disease death, the increase in risk were similar at 1-10 years (aRR 2.30, 95% CI 1.65, 3.20) 1 
and >10 years (aRR 2.21, 95% CI 1.73, 2.81) post-delivery. All studies on coronary heart 2 
disease death had a follow-up of >10 years, therefore we could not conduct further sensitivity 3 
analysis on duration of follow-up. 4 
 5 
Sensitivity analysis considering studies that adjusted for or had exclusions based on baseline 6 
age, body mass index (BMI) or weight, diabetes or gestational diabetes (GDM), smoking and 7 
hypertension between pre-eclampsia and control groups 8 
Sensitivity analyses were performed to consider age as a confounding factors in the 5 9 
cardiovascular outcomes that were significant in adjusted studies (Table 2). These showed 10 
that the risk remained significant in all outcomes: heart failure (aRR 3.89, 95% CI 1.83, 8.26), 11 
coronary heart disease (aRR 3.13, 95% CI 1.45, 6.75), coronary heart disease death (aRR 12 
2.63, 95% CI 1.74, 3.98), cardiovascular disease death (aRR 2.21, 95% CI 1.83, 2.66), and 13 
stroke (aRR 2.04, 95% CI 1.60, 2.60). 14 
The effect of pregestational BMI or weight and pregestational diabetes or GDM was 15 
examined for the heart failure, coronary heart disease and stroke outcomes. The risk for all 3 16 
outcomes remained significantly increased despite adjustment for BMI or weight (heart 17 
failure: aRR 2.74, 95% CI 1.10, 6.83; coronary heart disease: aRR 1.84, 95% CI 1.23, 2.74; 18 
stroke: aRR 1.94, 95% CI 1.42, 2.65) and diabetes or GDM (heart failure: aRR 3.89, 95% CI 19 
1.83, 8.26; coronary heart disease: aRR 2.16, 95% CI 1.03, 4.52; stroke: aRR 2.46, 95% CI 20 
1.11, 5.43). 21 
We considered the effect of pregestational smoking for coronary heart disease and 22 
stroke outcomes and found that the increased risk remained significant (coronary heart 23 
disease: aRR 1.56, 95% CI 1.11, 2.20; stroke: aRR 1.64, 95% CI 1.12, 2.40). However, when 24 
we examined the effect of pregestational hypertension for the coronary heart disease outcome, 25 
12  
the increase in risk was non-significant. We could not examine other important confounding 1 
factors, such as family history of cardiovascular disease or hypercholesterolaemia, due to the 2 
lack of studies presenting this data. 3 
The full cardiovascular risk factor profile of the pre-eclampsia and the control 4 
population is shown in Supplemental Table 5. There were significant differences in age, BMI, 5 
diabetes, smoking and blood pressure between the pre-eclampsia and control groups at 6 
baseline in 1,32 3,10, 19, 32 1,32 2,10, 19 and 1 studies,11 respectively, which only contributed to 7 
2% of total participant women. However, the cardiovascular risk factor profiles were not 8 
available in the majority of the studies included in this systematic review and meta-analysis. 9 
Only 3 studies had adjusted their results to account for the risk factor profile differences in 10 
age,32 BMI,10 diabetes,32 and smoking.10, 19 11 
 12 
Discussion 13 
In this systematic review and meta-analysis, 22 studies with over 6.4 million women 14 
were included. We showed an association of pre-eclampsia with future incident coronary 15 
heart disease, composite cardiovascular disease, heart failure, stroke and deaths due to 16 
coronary heart disease. The adjusted risk ranged between 1.8-2.5 fold compared to those 17 
without a history of pre-eclampsia in all cardiac outcomes, except in heart failure where a 18 
four-fold increase in risk was found. For coronary heart disease, heart failure and stroke, the 19 
increase in risk remained significant after adjusting for age, BMI and diabetes. Pre-eclampsia 20 
is a well-recognised risk factor for future hypertension. Our study confirms pre-eclampsia to 21 
be a risk factor for future cardiac disease although we are unable to determine whether this 22 
relationship is confounded by an adverse cardiovascular risk factor profile in patients with 23 
pre-eclampsia at baseline or whether pre-eclampsia is an independent risk factor. 24 
13  
Our meta-analysis supports previous literature in terms of a two-fold increased risk of 1 
cardiovascular disease death 39, 40 and stroke,41 but unique to this study, we conducted 2 
sensitivity analyses to consider the effects of potential confounding factors such as age, BMI, 3 
diabetes, hypertension and smoking, as well as examining the cardiovascular risk factors 4 
profiles at baseline. Compared with previous meta-analyses, we considered heart failure as a 5 
separate entity and showed a much higher risk than previously reported in composite cardiac 6 
outcomes.   7 
Due to the gaps in the current literature, it is difficult to ascertain whether 8 
confounding factors have contributed towards the associations we identified. After 9 
considering the effects of hypertension in the future coronary heart disease outcome, we 10 
found that the link between pre-eclampsia and future coronary heart disease was no longer 11 
statistically significant. This suggests that the association may be confounded by 12 
hypertension. We were unable to fully evaluate the effects of all confounding factors and 13 
undertake further sensitivity analysis due to the absence of such data in the included studies. 14 
The increased risk in future cardiovascular diseases may be driven by unmeasured 15 
confounders as none of the included studies have adjusted for all of the established 16 
cardiovascular risk factors such as age, BMI, diabetes, family history of cardiovascular 17 
disease, hypercholesterolaemia, hypertension and smoking. For instance, only 2 of the 4 18 
studies that examined heart failure had adjusted for pre-existing cardiovascular disease prior 19 
to delivery.23, 35 Pre-eclampsia and cardiovascular diseases are known to share risk factors. 20 
According to the American College of Obstetricians and Gynaecologists, the recognised risk 21 
factors for pre-eclampsia are: obesity, chronic hypertension, diabetes, chronic renal disease, 22 
previous pre-eclampsia, systemic lupus erythematosus, age over 40 years, primiparity, 23 
multiple pregnancy, in vitro fertilization and family history of pre-eclampsia.42 Apart from 24 
the pregnancy specific factors and age, all other risk factors overlap with those recognized by 25 
14  
American Heart Association 17 and American Stroke Association.16 These factors may be in 1 
the same causal pathways for cardiovascular diseases and it is difficult to establish whether 2 
pre-eclampsia is a predictor of cardiovascular events through distinct pathways or through 3 
inherent adverse cardiovascular profiles, such as obesity and hypertension, in women who 4 
develop pre-eclampsia. 5 
There is also a potential of confounding by pregnancy induced hypertension in 2 of 6 
the studies (Kessous 2015 32 and Hovsepian 2014 9) as women with pregnancy induced 7 
hypertension could have been included in the pre-eclampsia group. Historically it was 8 
thought that pregnancy induced hypertension is a milder form of pre-eclampsia, however it is 9 
increasing speculated that pre-eclampsia and pregnancy induced hypertension have separate 10 
underlying pathophysiological mechanisms with distinct cardiovascular consequences for the 11 
women and their offspring. Therefore, we have conducted additional sensitivity analyses in 12 
the stroke and cardiovascular disease outcomes where these 2 studies were excluded and 13 
showed that the increased risk persisted (Stroke: aRR 1.75, 95% CI 1.15, 2.65. 14 
Cardiovascular disease: RR 1.79, 95% CI 1.40, 2.31). 15 
A mechanistic link to explain the association between pre-eclampsia and future heart 16 
failure remains elusive. Pre-eclampsia has been found to be associated with a three-fold risk 17 
of future hypertension 40 and a doubling in risk of future diabetes.43 Therefore, heart failure in 18 
this group of women may be due to aetiologies other than ischaemic cardiomyopathy, for 19 
example hypertensive heart disease or diabetic cardiomyopathy. It has been suggested that 20 
the left ventricular (LV) remodelling and hypertrophy seen during pre-eclamptic pregnancies 21 
continues after the pregnancy.33 On the other hand, women with pre-existing LV dysfunction 22 
and placental insufficiency are more likely to develop pre-eclampsia than those with normal 23 
LV function, suggesting a correlation rather than causation.44 Furthermore, in peri-partum 24 
cardiomyopathy where a significant proportion of women continue to have LV dysfunction 25 
15  
years following delivery, the prevalence of pre-eclampsia is four times more common than in 1 
healthy pregnancies.45 2 
Risk stratification enables early identification of women at high risk of cardiovascular 3 
disease and allows optimization of targeted care towards prevention. There are several 4 
cardiovascular risk scores in use, though most were developed with an under-representation 5 
of women. The Reynolds risk score is gender-specific 46 and has been shown to perform 6 
better than the Framingham risk score in predicting cardiovascular events in women.47 7 
However, currently there are no risk calculators incorporating pregnancy complications. The 8 
American Heart Association has included pre-eclampsia and gestational hypertension as a 9 
risk factor for coronary artery disease and advocates active follow-up of risk factors.17 They 10 
suggest that pre-eclampsia manifesting in pregnancy is akin to a failed stress test of future 11 
vascular or metabolic disease. Using the Framingham prediction score, pre-eclampsia has 12 
been found to be independently associated with an increased 10-year cardiovascular risk 13 
score both at 3-8 years 48 and 18 years 49 follow-up intervals. 14 
The strength of our study is the large sample size from contemporary studies with a 15 
total of 45,938,256 patient-years follow-up. As a part of a larger programme of evidence 16 
synthesis, we used a comprehensive search strategy to examine the long-term cardiovascular 17 
outcomes in pre-eclampsia. The inclusion of more recent studies means that there is a greater 18 
likelihood of their findings being relevant and more generalizable to current practice. In our 19 
study, we used independent reviewers for performing double data extractions and for data 20 
analysis. The majority of the studies were designed to examine future cardiovascular diseases 21 
as their main outcome (n=21), and contribute to 99% of the women in our meta-analysis. 22 
The main limitation of our study is that significant unmeasured confounders may have 23 
contributed to our reported association between pre-eclampsia and future cardiovascular risk. 24 
Although most of the studies (n=20) have attempted to adjust for some potential confounding 25 
16  
factors, none of the studies included here have adequately adjusted for all relevant risk factors. 1 
In the few studies (2.6% of total participants) that reported baseline cardiovascular risk factor 2 
profiles, a majority of the cohort (2% of total participants) had significant baseline risk factor 3 
profile differences between the pre-eclamptic and the non-pre-eclamptic populations at index 4 
pregnancy. Other limitations include an inherent limitation from publication bias, where 5 
studies with positive findings are more likely to be published than those with negative or 6 
neutral results. As the majority were from retrospective studies, we had limited control over 7 
the quality of data collected. There could have been incomplete, inaccurate or inconsistent 8 
historical data on exposure as well as recall bias, which could have affected whether the case 9 
and control groups were ascribed correctly. In particular, four studies used questionnaire data 10 
to assess the cardiovascular outcomes.27, 30, 31, 37 Furthermore, we limited the studies to those 11 
in English, and may have missed important research data from non-English publications.  12 
Potential reasons for heterogeneity may be due to differences in the study population, 13 
research methodology and inherent differences between studies. As shown in Supplemental 14 
Table 1, 3 studies were conducted in ethnically diverse populations to the other studies, as 15 
they were conducted on the continent of Asia (Funai 2005,28 Kessous 2015,32 Lin 2011 & 16 
Tang 2009 23, 25), while the remainder were in Europe or North America. Two studies 17 
examined primiparous women only (Bhattacharya 2012,19 Wikstrom 2005 26), while the 18 
others studied women of any parity. Specific populations were analysed in two studies, which 19 
were Gordin 2007 29 (women with type 1 diabetes) and Stuart 2013 37 (nurses). 20 
In terms of methodology, Supplemental Table 3 shows that there were differences 21 
between methods of data collection and the actual type of data collected. Most of the data 22 
were collected through medical records or databases, where codes were employed to identify 23 
the outcomes. However, 5 studies utilised questionnaires or interviews (Andersgaard 2012,27 24 
Gordin 2007,29 Haukkamaa 2009,30 Kaaja 2005,31 Stuart 2013 37) and 2 studies performed 25 
17  
echocardiography (Ghossein-Doha 2014,38 Melchiorre 2011 33). Although codes are more 1 
objective, the research team is relying on historical accounts in the records from the clinician. 2 
On the other hand, though questionnaires, interviews or echocardiograms ensure direct 3 
patient contact with reliable outcome data collection, these methods are prone to selection 4 
bias from the research team. 5 
The leave out analyses for the main outcomes (Supplemental Table 6), demonstrates 6 
that there are underlying differences in the study cohorts that may also have contributed to 7 
the heterogeneity we observed. In the heart failure outcome, the heterogeneity was mainly 8 
driven by Mannisto 2013 within the adjusted studies.10 Compared with the other 3 studies, 9 
Mannisto et al. was the only study with a prospective design. For the coronary heart disease 10 
outcome, the heterogeneity was mainly from Lin 2011, which is the only research conducted 11 
in Asia within this group of studies.23 For both the coronary heart disease death and stroke 12 
outcomes, the heterogeneity was mainly driven by Bhattacharya 2012.19 In this study, the 13 
participants were younger in their index pregnancy with pre-eclampsia (out of the studies that 14 
included data on age during index pregnancy) compared with participants in the other studies. 15 
In the sensitivity analysis regarding duration of follow-up, the increased risk for heart 16 
failure was greater at 1-10 years compared with <1 year post-partum in the adjusted studies, 17 
however at >10 years postnatally, the risk was lower than that at 1-10 years and no longer 18 
significant. This may be due to a higher absolute risk in the control group during longer 19 
follow-up periods (i.e. >10 years). Therefore, the reduction in the relative risk may be a 20 
product of the higher baseline risk. Furthermore, the effect is exacerbated by the small 21 
sample size and number of events in the control group reported.10 22 
Further research is required to determine whether women with pre-eclampsia have an 23 
adverse cardiovascular risk factor profile at baseline which contributes to their increased risk 24 
of cardiovascular diseases in later life. The development of effective strategies towards 25 
18  
reducing these unfavourable risk profiles are required in order to plan the logistics for follow-1 
up of these women at high risk, such as where, when and how they should be followed-up 2 
and the type of intervention needed to rescue the progression of adverse events. The perinatal 3 
period is an opportune time for health screening, education, intervention and monitoring in 4 
at-risk women. In a focus group study, women with previous pre-eclampsia were found to be 5 
generally unaware of their increased risk of future cardiovascular diseases, but were 6 
motivated to undertake lifestyle modifications to reduce risk.50 In view of the burden and 7 
impact of cardiovascular disease on women in our society, we recommend a detailed cost-8 
benefit analysis to determine the postnatal timing for a screening programme in this high risk 9 
population. 10 
 11 
Conclusions 12 
Over 258,000 women with pre-eclampsia were examined in this meta-analysis of 22 13 
studies. We found that pre-eclampsia is linked with a four-fold increase in future heart failure. 14 
Significant unmeasured confounders may have contributed to the association we identified. 15 
In keeping with current recommendations, the findings from our study highlight the 16 
importance of patient education about risk and life style modifications to reduce risk, as well 17 
as regular monitoring of cardiovascular risk factors in women with a history of pre-eclampsia. 18 
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Table 1. Sensitivity analysis with regards to duration of follow-up. 
 
Outcomes  <1 year  1-10 years >10 years 
Cardiovascular 
disease death Adjusted - RR 2.30 (1.65-3.20), n=1 RR 2.21 (1.73-2.81), n=3 
Coronary heart 
disease 
Adjusted RR 3.10 (1.56-
6.15), n=1 
RR 3.78 (0.43-
77.30), n=2 
RR 1.46 (0.95-
2.25), n=3 
Unadjusted - - RR 2.09 (1.64-
2.66), n=3 
Coronary heart 
disease death 
Adjusted - - RR 2.10 (1.25-
3.51), n=4 
Heart failure Adjusted RR 4.10 (2.90-
5.80), n=1 
RR 8.42 (4.39-
16.17), n=2 
RR 1.60 (0.73-
3.50), n=1 
Unadjusted - RR 4.27 (2.09-
8.71), n=1 
RR 2.73 (1.30-
5.74), n=2 
Stroke Adjusted RR 2.22 (1.73-
2.85), n=2 
RR 3.56 (0.52-
24.28), n=2 
RR 1.18 (0.95-
1.46), n=2 
Unadjusted - - RR 1.60 (1.47-
1.74), n=1    
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Table 2. Sensitivity analysis with regards to age, pregestational body mass index or weight, 
pregestational smoking, pregestational diabetes or gestational diabetes and pregestational 
hypertension. 
 
Outcomes Age BMI / 
Weight 
Diabetes / 
GDM 
Smoking Hypertension 
Cardiovascular 
mortality 
RR 2.21 
(1.83-
2.66), 
n=4 
- - - - 
Coronary heart 
disease 
RR 3.13 
(1.45-
6.75), 
n=5 
RR 1.84 
(1.23-
2.74), n=3 
RR 2.16 
(1.03-4.52), 
n=2 
RR 1.56 
(1.11-2.20), 
n=4 
RR 3.84 (0.81-
18.16), n=3 
Coronary heart 
disease death 
RR 2.63 
(1.74-
3.98), 
n=3 
- - - - 
Heart failure RR 3.89 
(1.83-
8.26), 
n=3 
RR 2.74 
(1.10-
6.83), n=2 
RR 3.89 
(1.83-8.26), 
n=3 
- - 
Stroke RR 2.04 
(1.60-
2.60), 
RR 1.94 
(1.42-
2.65), n=3 
RR 2.46 
(1.11-5.43), 
n=3 
RR 1.64 
(1.12-2.40), 
n=4 
- 
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n=5 
BMI - Body Mass Index; GDM – Gestational Diabetes 
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Figure 1. Flow diagram of study inclusion. 
 
PRISMA 2009 Flow Diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Id
en
tif
ic
at
io
n 
El
ig
ib
ili
ty
 
In
cl
ud
ed
 
Sc
re
en
in
g 
Records identified through EMBASE and MEDLINE database searching between 2005 to August 2015  (N = 9,964). 
Full-text articles excluded (N = 58). 
• Did not evaluate CVD as an 
outcome (N = 52). 
• Studied maternal placental 
syndrome/ hypertensive disorders 
in pregnancy rather than pre-
eclampsia (N = 4). 
• Never pregnant control group (N = 
1). 
• Case-control study of CVD vs no 
CVD (N = 1). 
Full-text articles assessed for eligibility (N = 76). 
 
Title and abstract screened for potential inclusion (N = 9,964). Records excluded which did not meet the inclusion criteria on reviewing the titles and abstracts (N = 9,888). 
 
Studies included after full review of studies (N = 18). 
Full text articles included from citations 
of reviews and meta-analyses (N = 4). Total number of studies included in systematic review (N = 22). 
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Figure 2. Risk of heart failure with pre-eclampsia. 
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Figure 3. Risk of coronary heart disease with pre-eclampsia. 
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Figure 4. Risk of coronary heart disease death with pre-eclampsia. 
 
 
 
 
Figure 5. Risk of cardiovascular disease death with pre-eclampsia. 
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Figure 6. Risk of stroke with pre-eclampsia. 
 
 
